financetom
Business
financetom
/
Business
/
Johnson & Johnson Insider Sold Shares Worth $930,113, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson Insider Sold Shares Worth $930,113, According to a Recent SEC Filing
Sep 4, 2024 8:56 AM

04:51 PM EDT, 09/03/2024 (MT Newswires) -- Robert J Decker, Vice President, Corporate Controller, on August 30, 2024, sold 5,635 shares in Johnson & Johnson ( JNJ ) for $930,113. Following the Form 4 filing with the SEC, Decker has control over a total of 19,721 shares of the company, with 18,973 shares held directly and 748 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/200406/000122520824008326/xslF345X05/doc4.xml

Price: 167.00, Change: -0.16, Percent Change: -0.10

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise
Jun 3, 2024
04:27 AM EDT, 06/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) said on Sunday data from Cohort B of Phase 1b/2 study evaluating its experimental combination therapy of etrumadenant, zimberelimab, and chemotherapy could meaningfully improve clinical outcomes for people with metastatic colorectal cancer who have failed at least two prior treatments. The companies...
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients
Jun 3, 2024
04:32 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 trial showed its Imfinzi drug reducing the risk of death by 27% versus placebo in patients with limited-stage small-cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy. The company said the drug, also known as durvalumab, is the first and only immunotherapy...
Maersk faces significant port congestion in Asia, Mediterranean
Maersk faces significant port congestion in Asia, Mediterranean
Jun 3, 2024
OSLO (Reuters) - Maersk faces significant terminal congestion in Mediterranean and Asian ports, causing substantial delays in its vessel schedule, the Danish shipping group said in a statement on Monday. As a result of the congestion, the company will skip two westbound sailings from China and South Korea that had been planned to depart in early July, it added. ...
S&P Global's Platts Launches New Daily Assessments of Poultry, Beef Prices
S&P Global's Platts Launches New Daily Assessments of Poultry, Beef Prices
Jun 3, 2024
04:43 AM EDT, 06/03/2024 (MT Newswires) -- Platts said Monday it has launched new daily bulk-market price assessments for poultry and beef markets in the Americas, Asia, and the Middle East. The Standard & Poor's (SPGI) Global Commodity Insights company said the assessments will be accessible through the newly launched platform Platts Protein Daily. The publication includes a mix of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved